Celgene Withdraws EU Filing For Revlimid After Second CHMP Refusal
This article was originally published in The Pink Sheet Daily
Executive Summary
Company counters setback by unveiling promising lenalidomide data from NHL, newly diagnosed multiple myeloma trials during ASCO.